(Q43252417)

17 November 2017

title

Dabigatran: clinical pharmacology (English)

1 reference

17 November 2017

1 reference

P Mismetti

1

1 reference

17 November 2017

S Laporte

series ordinal

2

1 reference

17 November 2017

language of work or name

French

0 references

publication date

1 September 2009

1 reference

French Annals of Anesthesia and Reanimation

17 November 2017

published in

1 reference

17 November 2017

volume

28

1 reference

17 November 2017

issue

9 Suppl

1 reference

17 November 2017

page(s)

S8-14

1 reference

https://api.crossref.org/works/10.1016%2FS0750-7658%2809%2972459-1

17 November 2017

1 reference

7 January 2021

Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.

1 reference

https://api.crossref.org/works/10.1016%2FS0750-7658%2809%2972459-1

7 January 2021

A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0750-7658%2809%2972459-1

7 January 2021

Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).

1 reference

https://api.crossref.org/works/10.1016%2FS0750-7658%2809%2972459-1

7 January 2021

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0750-7658%2809%2972459-1

7 January 2021

Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0750-7658%2809%2972459-1

7 January 2021

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0750-7658%2809%2972459-1

7 January 2021

Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate

1 reference

https://api.crossref.org/works/10.1016%2FS0750-7658%2809%2972459-1

7 January 2021

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0750-7658%2809%2972459-1

7 January 2021

Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS0750-7658%2809%2972459-1

7 January 2021

Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment

1 reference

https://api.crossref.org/works/10.1016%2FS0750-7658%2809%2972459-1

7 January 2021

Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0750-7658%2809%2972459-1

7 January 2021

Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants

1 reference

https://api.crossref.org/works/10.1016%2FS0750-7658%2809%2972459-1

7 January 2021

Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0750-7658%2809%2972459-1

7 January 2021

Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0750-7658%2809%2972459-1

7 January 2021

Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0750-7658%2809%2972459-1

7 January 2021

A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays.

1 reference

https://api.crossref.org/works/10.1016%2FS0750-7658%2809%2972459-1

7 January 2021

10.1016/S0750-7658(09)72459-1

Identifiers

DOI

1 reference

17 November 2017

1 reference